Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Cytori Therapeutics Inc    CYTX

 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2016 9,60 M
EBIT 2016 -20,1 M
Net income 2016 -23,4 M
Debt 2016 -
Yield 2016 -
Sales 2017 12,4 M
EBIT 2017 -12,4 M
Net income 2017 -18,6 M
Debt 2017 -
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales2016 4,67x
Capi. / Sales2017 3,61x
Capitalization 44,9 M
More Financials
Company
Cytori Therapeutics, Inc. is a late stage cell therapy company.Its develops autologous cell therapies from adipose tissue, using its proprietary technology, to treat a variety of medical conditions.Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy™ acts principally... 
More about the company
Surperformance© ratings of Cytori Therapeutics Inc
Trading Rating : - Investor Rating :
More Ratings
Latest news on CYTORI THERAPEUTICS INC
08/18 CYTORI THERAPEUTICS : Announced Inducement Grant for New Employee
08/11 CYTORI THERAPEUTICS : Reports Second Quarter 2016 Business and Financial Results
08/05 CYTORI THERAPEUTICS : Management's Discussion and Analysis of Financial Conditio..
08/05 CYTORI THERAPEUTICS : reports 2Q loss
08/04 CYTORI THERAPEUTICS, INC. : Results of Operations and Financial Condition, Chang..
07/28 CYTORI THERAPEUTICS : Cell Therapy™ Phase I Trial Reports Maxillofacial Bo..
07/25 CYTORI THERAPEUTICS : What Do All These Investigator-Initiated Studies Mean to C..
07/14 CYTORI THERAPEUTICS, INC. : Changes in Registrant's Certifying Accountant, Finan..
07/07 CYTORI THERAPEUTICS : Cell Therapy Receives Limited Approval for Osteoarthritis ..
07/07 CYTORI THERAPEUTICS : ATHENA Trial for Chronic Ischemic Cardiovascular Disease
More news
Sector news : Medical Equipment, Supplies & Distribution - NEC
08/10 FTSE notches up fifth day of gains on firm financials
08/04 Business groups sue over new U.S. limit on tax-driven foreign buyouts
08/04DJBECTON DICKINSON : Tops Earnings Views, Cuts Revenue Guidance
08/04DJBECTON DICKINSON : Tops Earnings Views, Cuts Revenue Guidance
07/28DJZIMMER BIOMET : Boosts Bottom End of Earnings Forecast as Loss Narrows
More sector news : Medical Equipment, Supplies & Distribution - NEC
News from SeekingAlpha
05/10 Cytori Therapeutics' (CYTX) CEO Marc Hedrick on Q1 2016 Results - Earnings Ca..
05/10 Cytori Therapeutics EPS in-line, beats on revenue
05/10 Cytori Cell Therapy an Orphan Drug in Europe for scleroderma-related hand dys..
05/09 Notable earnings after Tuesday?s close
03/24 Cytori's late-stage study of ECCS-50 in scleroderma 50% enrolled; study to co..
Advertisement
Chart CYTORI THERAPEUTICS INC
Duration : Period :
Cytori Therapeutics Inc Technical Analysis Chart | CYTX | US23283K1051 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 7,33 $
Spread / Average Target 235%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Marc H. Hedrick President, Chief Executive Officer & Director
David M. Rickey Chairman
Tiago Girão CFO, Vice President & Head-Investor Relations
Steven Kesten Chief Medical Officer & Executive Vice President
John K. Fraser Chief Scientist
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CYTORI THERAPEUTICS IN..-4.14%45
MEDTRONIC PLC14.14%122 351
BAXTER INTERNATIONAL I..25.77%26 096
ZIMMER BIOMET HOLDINGS..26.49%25 956
C R BARD INC14.91%15 990
TERUMO CORP14.69%15 924
More Results